CureVac (CVAC) News Today $2.56 +0.07 (+2.81%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Is CureVac N.V. (CVAC) the Best German Stock to Buy Now?November 20 at 9:39 AM | msn.comLeerink Partners Sticks to Their Hold Rating for CureVac (CVAC)November 15, 2024 | markets.businessinsider.comCureVac: Strong Financial Position and Promising Pipeline Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comCureVac Reports Significant Revenue Growth Amid Strategic RestructuringNovember 13, 2024 | markets.businessinsider.comCureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...November 13, 2024 | uk.finance.yahoo.comCureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...November 13, 2024 | uk.finance.yahoo.comCureVac reports Q3 revenue EUR 493.9M vs. EUR 16.5M last yearNovember 13, 2024 | markets.businessinsider.comCureVac Reports Surging Revenues and Profit GrowthNovember 13, 2024 | markets.businessinsider.comCureVac N.V. (CVAC) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comCureVac (CVAC) to Release Earnings on TuesdayCureVac (NASDAQ:CVAC) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 8, 2024 | marketbeat.comCureVac presents new, updated data at mRNA Health ConferenceNovember 6, 2024 | markets.businessinsider.comCureVac Appoints New CFO to Drive GrowthNovember 5, 2024 | markets.businessinsider.comCureVac’s Latest mRNA Advances Spark Investor InterestNovember 5, 2024 | markets.businessinsider.comCureVac (NASDAQ:CVAC) Shares Up 3.9% - Should You Buy?CureVac (NASDAQ:CVAC) Stock Price Up 3.9% - Still a Buy?October 29, 2024 | marketbeat.comEQS-News: CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 28, 2024 | markets.businessinsider.comCureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 28, 2024 | finance.yahoo.comCureVac (NASDAQ:CVAC) Shares Gap Up - Should You Buy?CureVac (NASDAQ:CVAC) Shares Gap Up - Should You Buy?October 9, 2024 | marketbeat.comCureVac: Back To Square OneOctober 8, 2024 | seekingalpha.comPfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patentsOctober 8, 2024 | reuters.comCureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comPoint72 Asset Management L.P. Invests $8.24 Million in CureVac (NASDAQ:CVAC)Point72 Asset Management L.P. purchased a new stake in CureVac (NASDAQ:CVAC - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,422,728 shares of the company's stock, valued at approximately $8,237,000. Point72 AOctober 2, 2024 | marketbeat.comCureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firmsOctober 1, 2024 | finance.yahoo.comCureVac (NASDAQ:CVAC) Shares Down 7.3% CureVac (NASDAQ:CVAC) Stock Price Down 7.3%September 16, 2024 | marketbeat.comCureVac's (CVAC) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a report on Monday.September 16, 2024 | marketbeat.comCureVac's cancer vaccine shows promise in early trialSeptember 15, 2024 | uk.investing.comCureVac’s Promising Cancer Vaccine Candidate CVGBM Elicits Buy RatingSeptember 13, 2024 | markets.businessinsider.comEQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 CongressSeptember 13, 2024 | markets.businessinsider.comEQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramSeptember 13, 2024 | markets.businessinsider.comGSK, CureVac mRNA flu shot reaches late-stage studiesSeptember 12, 2024 | seekingalpha.comCureVac (NASDAQ:CVAC) Trading Up 9.9%CureVac (NASDAQ:CVAC) Trading 9.9% HigherSeptember 9, 2024 | marketbeat.comEQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 CongressSeptember 9, 2024 | markets.businessinsider.comCureVac (CVAC) Receives a Hold from Deutsche BankSeptember 2, 2024 | markets.businessinsider.comCureVac (NASDAQ:CVAC) Short Interest Down 10.0% in AugustCureVac (NASDAQ:CVAC - Get Free Report) saw a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 5,650,000 shares, a decline of 10.0% from the July 31st total of 6,280,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 5.0 days. Currently, 6.1% of the company's shares are sold short.September 1, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (DNA.MX)August 23, 2024 | sg.finance.yahoo.comNews Flash: 8 Analysts Think CureVac N.V. (NASDAQ:CVAC) Earnings Are Under ThreatAugust 21, 2024 | finance.yahoo.comCUREVAC (1CVAC.MI)August 20, 2024 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)August 20, 2024 | markets.businessinsider.comCureVac (NASDAQ:CVAC) Price Target Cut to $16.00 by Analysts at JMP SecuritiesJMP Securities decreased their price objective on CureVac from $18.00 to $16.00 and set a "market outperform" rating on the stock in a report on Friday.August 16, 2024 | marketbeat.comCureVac: A Promising Buy Amidst Financial Stability and Innovative Vaccine PipelineAugust 16, 2024 | markets.businessinsider.comEQS-News: CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected GlioblastomaAugust 15, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business UpdateAugust 15, 2024 | markets.businessinsider.comCureVac (NASDAQ:CVAC) Shares Down 2.1% CureVac (NASDAQ:CVAC) Stock Price Down 2.1%August 15, 2024 | marketbeat.comCureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected GlioblastomaAugust 15, 2024 | finance.yahoo.comCureVac (NASDAQ:CVAC) Shares Down 10.7% CureVac (NASDAQ:CVAC) Trading Down 10.7%August 5, 2024 | marketbeat.comWe Think CureVac (NASDAQ:CVAC) Can Afford To Drive Business GrowthAugust 1, 2024 | finance.yahoo.comCureVac (NASDAQ:CVAC) Shares Down 3.7% CureVac (NASDAQ:CVAC) Stock Price Down 3.7%July 23, 2024 | marketbeat.comCVAC Aug 2024 2.000 put (CVAC240816P00002000)July 22, 2024 | finance.yahoo.comCureVac (NASDAQ:CVAC) Trading 11% Higher CureVac (NASDAQ:CVAC) Stock Price Up 11%July 15, 2024 | marketbeat.comCureVac (NASDAQ:CVAC) Shares Gap Up to $3.11CureVac (NASDAQ:CVAC) Shares Gap Up to $3.11July 11, 2024 | marketbeat.comAgomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial OfficerJuly 11, 2024 | businesswire.com Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address A “Thank You Gift” From Pres. Trump - Genius (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide CVAC Media Mentions By Week CVAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVAC News Sentiment▼0.690.48▲Average Medical News Sentiment CVAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVAC Articles This Week▼12▲CVAC Articles Average Week Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARWR News Today LGND News Today WVE News Today KROS News Today AKRO News Today AMPH News Today MIRM News Today CNTA News Today SUPN News Today MNKD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CVAC) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredCan Trump Make Housing Great Again?Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflatio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
